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Summary 
It has recently been shown that the minor lymphocyte stimulating-like  products expressed by 
some mice are actually encoded by open reading frames in the 3' long terminal repeats of mouse 
mammary tumor viruses. These products act as viral superantigens (vSAGs). That is, they stimulate 
most T  cells bearing particular  V3s almost regardless of the rest of the variable components 
of the T  cell receptors expressed by those cells. To find out more about the structure of these 
vSAGs, a set of truncated vSAG genes was used in transfection and in vitro translation experiments 
to show that the functional vSAG is a type II integral membrane protein with a large glycosylated 
extracellular  COOH-terminal  domain  and  a  small,  nonessential,  intracellular  NH2-terminal 
cytoplasmic domain. These results are consistent with the fact that the vSAGs must be expressed 
on the cell surface in order to interact with T cells and class II major histocompatibility complex 
proteins.  They also account for the finding  that  much of the V3 specificity of the vSAGs is 
controlled by amino acids at the COOH-terminal  end of the vSAG proteins,  amino acids that 
will be extracellular  in type II proteins. 
I 
t is almost 20 years since Festenstein (1) discovered the Mls 
loci in mice. At the time he identified their products by 
their ability to stimulate very powerful mixed lymphocyte 
reactions between spleen cells of mice identical at their MHC 
loci, but different in background genes. Since the discovery 
of Mls, it has been shown that the products of these genes, 
in conjunction with class II MHC proteins,  stimulate Mls- 
disparate T cells (2, 3). Also, it is now known that Mls prod- 
ucts are superantigens, antigens that bind to MHC and stimu- 
late virtually all T cells bearing particular V3 regions as part 
of their receptors (4, 5). It is this property that makes some 
of the Mls products such powerful T  cell stimulants.  Mice 
have only about 20 different V3 regions available for use as 
part of their receptors and therefore any given Mls product 
will stimulate 5% or more of the T  cells in a mouse of ap- 
propriate MHC type. 
Although the phenomena of Mls have been known for some 
time, it was not until recently that the genes coding for Mls 
products were identified. Various Mls-like products have now 
been  shown  to  map  concordantly  with  mouse mammary 
tumor virus  (MTV) 1 integrants  in the genomes of certain 
strains of mice (6-10).  In the case of two exogenous MTVs, 
we and others have shown that their associated viral superan- 
I Abbreviations used in this paper: exoMTV,  exogenous  mouse mammary 
tumor virus;  ORE open reading  frame; vSAG, viral  superantigen. 
tigens (vSAGs) are encoded by the open reading frames (ORFs) 
in the 3' LTRs of the viruses (10-12).  The exact structure 
of the product of the vSAG gene was, however, heretofore 
unknown. 
To find out more about the actual structure of the vSAg 
protein,  we constructed full-length  and truncated versions 
of the  gene  encoded  by  the  C3H/HeJ  exogenous  MTV 
(exoMTV) and studied the properties of their protein prod- 
ucts.  We report  here that  the exoMTV vSAG is a type II 
membrane-bound glycoprotein, with a core protein of 37 kD 
(the predicted molecular mass of the full-length OR.F gene 
protein product), and that most of the short NH2-terminal 
cytoplasmic tail of this protein is not essential for its function. 
Materials and Methods 
Construction of ORF Wild-Type and Truncated Genes.  The syn- 
thesis of the exoMTV full-length ORF gene was described previ- 
ously (11). Briefly, this coding region (ORFml) was amplified from 
a fragment  of MTV containing  env and the 3' LTR (a gift  of 
Dr. J. Majors, Washington University, St. Louis, MO) using a PCR 
(13) and MTV-specific 5' and 3' oligonucleotides. Truncated ver- 
sions of the gene, ORFm2-m5, were produced in similar fashion. 
The sequences of the 5' primers for these constructs  were as fol- 
lows: 5'-~TCGAGA.W_,CCGCGCC~oCAG-3',  ORFml; 
5  '-GGGAATTCCGC_,GATGAGCCCATCAGACAAAG-Y,  ORFm2; 
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CTATGTTAAGAAATGAATCATTA-Y,  ORFm4; 5'-GGGAATTC- 
CG~AATAGAAAATAGA-3', ORFm5. The 3' primer for 
all the ORF genes was  5'-C,C,C~ATCCTCTAGAC,  C~AACCG- 
CAAGGTTGC~-Y.  The amplified products  were  cloned  into 
pTZ18K (Pharmacia Fine Chemicals, Piscataway, NJ), sequenced, 
and ligated into the mammalian expression vector pBDWMC/~2, 
as described previously (11, 14). 
Transfection of ORF Gene Products.  The full-length and trun- 
cated OKF genes, ORFml-m5, were transfected into the B cell 
hybridoma, LBB.1 (11, 15). Transfectants were selected by growth 
in G418 and were screened for expression of TCR CB mRNA, 
encoded by pBDWMCB2, by Northern blot analysis using a mouse 
C# probe. 
In Vitro Protein Synthesis.  The ORFml-3 sequences carried in 
pTZ18K plasmids were used to synthesize capped mKNAs in vitro 
with T7 RNA polymerase using the in vitro transcription kit as 
suggested by the supplier (Stratagene, La  JoLla, CA). 1 #g of  capped 
mRNA was subjected to in vitro translation with a rabbit reticulo- 
cyte lysate preparation (Promega Biotec, Madison, WI). In some 
cases canine microsomal membranes (Promega Biotec) were added 
to the translation cultures. Synthesized protein was labeled by the 
addition of 3SS-methionine and 3sS-cysteine to the reaction mix- 
tures. Products were analyzed on 10% SDS-polyacrylamide gels. 
To demonstrate how much of the OKF proteins was transported 
into microsomes, in some cases translation products obtained in 
the presence of microsomal membranes were incubated for 10 min 
on ice with 50 #g/ml proteinase K with or without 0.1% Triton 
X-100 before analysis on SDS-polyacrylamide gels. 
Assay of ORF Function.  LBB.1  transfectants were screened for 
their ability to stimulate the T cell hybridomas K14-15.11 (V/$14  +) 
and KOX15-8.3 (V/~15  +) because the vSAg encoded by exoMTV 
is known to stimulate mouse T cells bearing either of these V/~s 
(11). The T cell hybridomas DO-11.10/$4.4 (V~8.2 +) and KOXT- 
6.6 (V/~7  +) were used as positive and negative controls, respec- 
tivdy. T cells  beating VB8.2 are not stimulated by any of  the vSAgs 
expressed endogenously by LBB.1. T ceils bearing V/37 are stimu- 
lated by an LBB.1 endogenous vSAg (11). Stimulation of the hy- 
bridomas was assayed by lymphokine production as previously de- 
scribed (16). 
Results 
Which  Methionine  Is  the  Start  Site for Active  ORF  Pro- 
reins?  The predicted protein sequence of the ORF gene from 
C3H/HeJ exoMTV is shown in Fig. 1 (17, 18). The sequence 
contains more than five methionine residues. Since the product 
of the OKF gene has never been detected in vivo, the actual 
translation initiation site was unknown. The longest protein 
that might be encoded by the OKF gene would be 37 kD, 
but other potential start sites would encode proteins of "~33, 
"~23,  '~20,  and •18  kD. 
To find out which methionine was actually used as the 
start  site  by  the  exoMTV  OKF  product,  four  NH2- 
terminally truncated ORF genes were created that would allow 
initiation of  protein synthesis at successive methionines within 
the molecule (ORF sm2-5). These genes, and a control full- 
length exoMTV ORF gene (ORFml), were cloned into the 
mammalian expression vector, pBDWMCB2, and transfected 
into MHC class II-expressing LBB.1 B hybridoma cells. Tram- 
fectants were assayed for stimulation of T  cell hybridomas 
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Figure 1.  The predicted amino acid sequence  of exoMTV ORE The 
sequence is deduced from the DNA sequence reported for this gene in 
references 17 and 18. Potential  sites for N-linked glycosylation  are indi- 
cated by asterisks. A potential  signal peptide/transmembrane  hydrophobic 
region is also marked. The expected  sizes of the protein encoded  by the 
full-length and truncated ORF genes are shown in parentheses  beside the 
names of each gene. 
expressing V314 and V315, the targets of the exoMTV vSAG 
(11). The results of a representative experiment are illustrated 
in Fig.  2.  As previously shown (11), the untransfected cell 
line, LBB.1, failed to stimulate K14-15.11 (VB14) and KOX15- 
LBB.1 
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Figure 2.  The effect  of NH2-terminal truncation  on the superantigen 
activity  of exoMTV  ORE LBB.1  B lyrnphoma  cells transfected  with full- 
length or truncated  MTV ORF genes  were  tested  for their  ability  to stimu- 
late various T cell hybridomas as previously  described (16). Stimuhtion 
was assayed  24 h later by levels of secreted  lymphokines  in the superna- 
rants. (1~) Response  of K14-15.11 (VB14  +); (1~) response of KOX15-8.3 
(VB15+); (I) response  of DO-11.10 (V/38.2+); ([]) response  of KOX7- 
6.6 (VB7+). 
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was purified from untransfected LBB.1 and the ORF transfected deriva- 
tives, and analyzed by Northern blotting as previously described. Mes- 
senger RNA from the transfected ORF constructs was detected using a 
mouse TCR CB probe, which detects the 3' untranslated  region of the 
construct mRNA (11). The amount of RNA loaded in each lane was nor- 
realized by the amount of RNA hybridized with a probe for glyceralde- 
hyde phosphate  dehydrogenase (GAPDH). 
8.3 (V~15). Transfectants expressing OKFs truncated to the 
third methionine in the predicted protein and beyond (LBB.1- 
OKFm3-5) were also inactive in this assay. Transfectants car- 
tying the full-length ORF gene, or a truncated OKF gene 
that could initiate at the second methionine (LBB.1-ORFml 
and LBB.1-OKFm2,  respectively), were active in this assay. 
LBB. 1-ORFm2 was less efficient than LBB.1-OKFml, how- 
ever. A V~/8.2  + T cell hybridoma, DO-11.10/$4.4,  was not 
stimulated by any of the B cell lines, as expected.  All the 
B cell lines had the ability to present MTV vSAGs expressed 
within them to T cells, since all the B cell lines stimulated 
a VB7-bearing T  cell hybridoma, KOX7-6.6,  by means of 
a VB7-specific vSAG endogenous to LBB.1 (11; Dr. L.  Ig- 
natowicz,  personal communication). 
To check that all these cell lines expressed the transfected 
OKF genes at comparable levels, mKNA was prepared from 
the different transfectants and analyzed by Northern blot for 
expression of mouse CB mRNA. In pBDWMCB2 constructs, 
the OtLF genes and variants are encoded upstream of  the mouse 
C~/2 gene, which will be cotranscribed with the ORF genes 
themselves. Expression of C/~2 mRNA in these transfectants 
should, therefore, accurately reflect transcription  of the var- 
ious ORF constructs.  The LBB.1 transfectants could not be 
analyzed for expression of the transfected OKF genes them- 
selves  because LBB.1 expresses  several  endogenous ORF genes 
that would crosshybridize extensively with the transfected 
gene products. Transfected  mRNA was also analyzed for levels 
of GAPDH mRNA, which is mRNA for a housekeeping 
gene. 
As  shown in Fig.  3,  LBB.I-ORFml  expresses less C~ 
mRNA by comparison with GAPDH mRNA than the other 
transfectants. The other transfectants express roughly equiva- 
lent levels of C~ mRNA. These data show that the results 
described above are not the consequence of  low ORF mRNA 
expression in the inactive transfectants. They also suggest that 
the difference in activity between LBB.I-ml and LBB.I-m2 
is not due to lower levels of OKF expression in the latter 
cell line, but rather may be due to stronger activity on the 
part of the full-length ORF protein. 
These results establish several  points. First, they show that 
the ORF protein initiating from either the first or second 
methionine residue can function as a vSAG with proper V~ 
specificity. Second, internal methionine residues COOH ter- 
minal to the second methionine cannot initiate an ORF gene 
product with superantigenic properties. Finally, the first 38 
amino acids of the predicted protein sequence of full-length 
exoMTV ORF are not essential for the function of the pro- 
tein, although they may contribute somewhat to the efficiency 
with which it acts. 
Can  the  ORF Protein Be  Transported into Microsomes and 
Glycosylated?  If the ORF protein is to be recognized by T 
cells it must find its way to the cell surface. The predicted 
product of the ORF gene does have a single hydrophobic 
region (Fig. 1), which could act as a signal peptide and/or 
transmembrane region. If the protein is transported into the 
microsomal compartment it  should  be glycosylated.  The 
predicted sequence for the ORF product does have five poten- 
tial sites for N-linked glycosylation, all, interestingly enough, 
COOH terminal of the hydrophobic stretch of amino acids 
(Fig.  1).  To find out whether or not the protein could be 
glycosylated, and, if so, to determine the function of the hy- 
drophobic region in this process, we used in vitro translation 
systems to synthesize the protein. 
The ORFml, ORFm2, and ORFm3 genes described above 
were used as substrates for mRNA synthesis. Equal amounts 
of mRNA were translated in vitro using a rabbit  reticulo- 
cyte lysate system, and analyzed by SDS-PAGE. Each tran- 
script produced proteins of the expected size (Fig. 4 A, left). 
That is, ORFml, ORFm2, and OKFm3 transcripts yielded 
proteins of 37, 33, and 23 kD, respectively, although in each 
case some initiation of translation was seen from subsequent 
internal methionines as well. All the transcripts were trans- 
lated in vitro with roughly the same efficiency. 
To study the cotranslational processing or modification of 
these proteins, the same mKNAs were translated in vitro in 
the presence  of  microsomal membranes (Fig. 4 A, right). When 
either the ORFml or ORFm2 transcripts  were translated 
in the presence of microsomal membranes,  four additional 
bands with higher molecular masses than the core proteins 
of 37 and 33 kD appeared, consistent with glycosylation of 
the core proteins at four of the five  potential N-linked glycosy- 
lation sites contained in these proteins (Fig. 1). Perhaps steric 
hindrance prevents glycosylation on the same protein mole- 
cule at both the nearly adjacent sites at residues 89 and 93. 
For both ORFml and OKFm2 products, the glycosylated 
forms of the proteins  lay on a ladder with intervals of •3 
kD, the expected molecular mass of an immature N-linked 
sugar complex. Despite the presence  of  two potential N-linked 
glycosylation sites in the mOKF3 product, there was no evi- 
dence for its glycosylation in the presence of microsomes. 
These results showed that the OKFml or OKFm2, but 
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duct is a type II membrane span- 
ning glycoprotein. (A)  OKFml, 
ORFm2, and OKFm3 sequences 
carried  in  the  plasmid pTZ18R 
(Pharmada) were  used  to synthesize 
capped mRNAs in vitro. 1/zg of 
capped mRNA was subjected to 
in vitro translation  with a rabbit 
reticulocyte  lysate  preparation  with- 
out  (left) or with  (right) canine 
microsomal membranes (Promega 
Biotec). Synthesized  protein  was la- 
beled by addition  of 3sS-methionine 
and  3sS-cysteine to  the  reaction 
mixture. Products  were  analyzed  on 
10% SDS-polyacrylamide  gels.  The 
band at 45 kD was present in all 
samples and  is  produced from 
mRNA contaminating the  tran- 
scription kit. (B) The in vitro trans- 
lation products  from  OR.Pml (left) 
or ORFm2  (right) prepared  with  ca- 
nine microsomal  membranes as in 
A were incubated  with proteinase 
K (50/,g/ml)  for 10 mill  on ice with 
or without  Triton  X-100 (0.1%) and 
analyzed on SDS-PAGE. 
not the ORFm3, gene products can be transported into the 
endoplasmic reticulum such that sites COOH terminal to 
the hydrophobic region can be N-glycosylated. Furthermore, 
the molecular masses of the translation products do not sug- 
gest any truncation of the protein in the endoplasmic retic- 
ulum. This result strongly suggests that the hydrophobic re- 
gion beginning at amino acid 45  of the full-length ORF 
protein acts as a signal peptide that is not cleaved after trans- 
port  into the endoplasmic reticulum. 
Is the ORF Protein an Integral Membrane Protein?  To confirm 
this result and determine whether the ORF product is an 
integral membrane protein, microsomal membranes containing 
ORFml or ORFm2 proteins were treated with proteinase 
K, and the protected protein fragments were analyzed by SDS- 
PAGE (Fig. 4 B). Most of the glycosylated ORFml protein 
(left) and all of the ORFm2 protein (right) was protected from 
proteinase K treatment unless the microsomes were disrupted 
by detergent. This confirmed that the vast majority of the 
protein ended up inside the endoplasmic reticulum. How- 
ever,  a  small portion  (~2  kD)  of the  ORFml,  but  not 
ORFm2, product was removed by proteinase K treatment, 
indicating that the small NH2-terminal portion present in 
the ORFml  product, but  absent from ORFm2,  carries  a 
protease-sensitive  site and remains outside the microsomes. 
This indicates that ORF is indeed a membrane protein with 
a  small cytosolic NH2-terminal  portion  and  a  transmem- 
brane region, with the majority being a COOH-terminal 
end in the extracellular compartment. 
Discussion 
Although Mls antigens, the MTV vSAGs, are recognized 
like conventional antigenic peptides in association with MHC 
by T ceils, the recent discovery that these products are super- 
antigens (4, 5) suggested that they may not act as peptides 
but rather as proteins of appreciable  size, comparable with 
that of the other well-characterized superantigens, the bac- 
terial toxins (19-21). 
The data in this paper strongly support this latter idea. 
The gene truncation experiments show that in order for the 
vSAG to engage T  cells, it must contain the hydrophobic 
region of amino acids near the NHz-terminal end of the pro- 
tein. The in vitro translation experiments described here show 
that this hydrophobic stretch of amino acids can act both 
as a signal peptide for transport into the endoplasmic retic- 
ulum and as a transmembrane region. 
The experiments described  here also  show,  perhaps sur- 
prisingly, that the MTV SAGs are type II membrane-bound 
proteins. Most membrane proteins are type I, that is their 
NH2-terminal  amino  acids  are  found  outside  and  their 
COOH-terminal amino acids lie inside the cell. Type II mem- 
brane proteins, on the other hand, have a single internal hy- 
drophobic region, which acts both as a signal peptide and 
as a transmembrane region, such that the COOH terminus 
of the protein is found extraceUularly, and the NH2 terminus 
is found in the cytoplasm (22-25).  Our finding that most 
of the vSAG protein is protected from proteases  after trans- 
port into microsomes, and that only a small NH2-terminal 
fragment can be digested in such experiments, shows that 
the vSAGs are likewise type II integral membrane proteins. 
This conclusion is consistent with the idea that the extremely 
variable COOH-terminal residues of this group of proteins 
may contribute to their V3 specificity  (11, 17,  18, 26-29). 
It is also consistent with our finding that the NH2-terminal 
cytoplasmic region is not absolutely required for vSAG func- 
tion, but may improve its efficiency. Also, the anchoring of 
850  Structural  Analysis  of a Mouse Mammary  Tumor Virus Superantlgen vSAGs in the plasma membrane should enhance their ability 
to interact with class II MHC molecules, a prerequisite for 
T  cell recognition. 
The hydrophobic putative signal peptide/transmembrane 
region of this protein is flanked by a negatively charged aspartic 
acid immediately on the NH2-terminal side,  a feature not 
characteristic of most type II proteins, which usually have 
a positively charged amino acid at this position (23-25). An- 
other unusual property of the hydrophobic region is an in- 
ternal  positively charged  lysine,  of unknown  functional 
significance, a feature shared with the transmembrane regions 
of the oe and ~ chains of the TCR (30, 31), where the func- 
tion appears to be to promote association with CD3 subunits 
that bear negatively charged amino acids in their transmem- 
brane regions. 
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